Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

This study, building on the lessons learned from the ADAPT Study; will further investigate the effectiveness and safety of a combination pharmacotherapy (XR-NTX; as Vivitrol® plus once-daily bupropion extended-release tablets) for methamphetamine use disorder. 

CTN Protocol ID: 
Completed ID: 

Principal Investigator(s)

Madhukar H. Trivedi, M.D.

University of Texas Southwestern Medical Center
Mood Disorders Research Program and Clinic

5325 Harry Hines Blvd, MC9119
Dallas, TX 75390
United States